Payment overview · 2025
General Payments
$602.36
35 reported records · 7 companies
Healthcare provider profile · identity verified
Junho Bok Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1245321462
Verified facts
What the public records show
CMS Open Payments records show Junho Bok Lee, MD received $602.36 in general payments during 2025 across 35 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 456 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 990 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $239.40 | 39.7% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $105.04 | 17.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.77 | 12.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.10 | 12.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.46 | 11.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.39 | 3.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.20 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $602.36 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $239.40 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.04 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.92 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $77.77 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $77.77 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.46 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.46 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 456 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 990 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
456 | 98 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
90 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
990 | 189 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
34 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2809 | 662 |
| Amlodipine Besylate | Amlodipine Besylate | 1700 | 396 |
| Vascepa | Icosapent Ethyl | 1357 | 247 |
| Metformin Hcl | Metformin Hcl | 1171 | 269 |
| Jardiance | Empagliflozin | 990 | 189 |
| Losartan Potassium | Losartan Potassium | 927 | 222 |
| Omeprazole | Omeprazole | 771 | 193 |
| Tamsulosin Hcl | Tamsulosin Hcl | 718 | 159 |
| Sertraline Hcl | Sertraline Hcl | 638 | 159 |
| Diclofenac Epolamine | Diclofenac Epolamine | 613 | 88 |
| Alendronate Sodium | Alendronate Sodium | 612 | 155 |
| Gabapentin | Gabapentin | 544 | 135 |
| Creon | Lipase/Protease/Amylase | 456 | 98 |
| Meloxicam | Meloxicam | 417 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 412 | 89 |
| Simvastatin | Simvastatin | 401 | 99 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 392 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 386 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 93 |
| Finasteride | Finasteride | 369 | 82 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 323 | 58 |
| Trazodone Hcl | Trazodone Hcl | 290 | 76 |
| Lisinopril | Lisinopril | 273 | 62 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 260 | 51 |
| Metformin Hcl Er | Metformin Hcl | 257 | 61 |
| Carvedilol | Carvedilol | 255 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 255 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 252 | 75 |
| Donepezil Hcl | Donepezil Hcl | 217 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 208 | 69 |
| Meclizine Hcl | Meclizine Hcl | 200 | 79 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 200 | 42 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 184 | 45 |
| Oxybutynin Chloride | Oxybutynin Chloride | 184 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 41 |
| Januvia | Sitagliptin Phosphate | 157 | 32 |
| Famotidine | Famotidine | 156 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 36 |
| Eliquis | Apixaban | 134 | 25 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 126 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 25 |
| Myrbetriq | Mirabegron | 124 | 26 |
| Ammonium Lactate | Ammonium Lactate | 122 | 34 |
| Montelukast Sodium | Montelukast Sodium | 122 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 105 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 31 |
| Mometasone Furoate | Mometasone Furoate | 92 | 48 |
| Prolia | Denosumab | 90 | 59 |
| Solifenacin Succinate | Solifenacin Succinate | 88 | 17 |
| Celecoxib | Celecoxib | 86 | 30 |
| Furosemide | Furosemide | 85 | 22 |
| Memantine Hcl | Memantine Hcl | 84 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 24 |
| Allopurinol | Allopurinol | 81 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 19 |
| Ozempic | Semaglutide | 79 | 20 |
| Enalapril Maleate | Enalapril Maleate | 74 | 15 |
| Alprazolam | Alprazolam | 73 | 20 |
| Glimepiride | Glimepiride | 70 | 20 |
| Rybelsus | Semaglutide | 70 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 52 |
| Zenpep | Lipase/Protease/Amylase | 66 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 64 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 14 |
| Farxiga | Dapagliflozin Propanediol | 62 | 18 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Glipizide Er | Glipizide | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | suppressed |
| Mirtazapine | Mirtazapine | 59 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 16 |
| Single Use Swab | Alcohol Antiseptic Pads | 57 | 25 |
| Vemlidy | Tenofovir Alafenamide | 56 | suppressed |
| Kerendia | Finerenone | 54 | suppressed |
| Fenofibrate | Fenofibrate | 53 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 52 | 11 |
| Linzess | Linaclotide | 50 | suppressed |
| Atenolol | Atenolol | 49 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 13 |
| Procto-Med Hc | Hydrocortisone | 48 | 15 |
| Azithromycin | Azithromycin | 47 | 40 |
| Telmisartan | Telmisartan | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 42 | 12 |
| Lidocaine | Lidocaine | 42 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 41 | suppressed |
| Ramelteon | Ramelteon | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 40 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Brilinta | Ticagrelor | 39 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Hydrocortisone | Hydrocortisone | 34 | 20 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 13 |
| Fenofibrate | Fenofibrate,micronized | 32 | 12 |
| Clotrimazole | Clotrimazole | 31 | 18 |
| Colchicine | Colchicine | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 13 |
| True Comfort Alcohol Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 21 |
| Alcohol Swab | Alcohol Antiseptic Pads | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 12 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Exemestane | Exemestane | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $602.36 · 35 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, CREON, FARXIGA, JARDIANCE, Kerendia, LINZESS, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error